The physician on the CDC advisory board expects the break to be lifted

A member of a key CDC advisory body told CNBC Friday morning that he expects the U.S. hiatus on Johnson & Johnson’s one-off coronavirus vaccine to be lifted at some point.

“I think we are ready to use this vaccine. We had to take an important pause to review this safety information to consider the risks. But I think there is a large amount of evidence that the Benefit far outweighs this risk, “said Dr. Wilbur Chen, professor in the University of Maryland School of Medicine.

Chen spoke on the Worldwide Exchange before attending a meeting of the Agency’s Advisory Committee on Immunization Practices later on Friday to discuss the rare but serious bleeding disorder some women had after receiving the J&J shot.

In addition to the six patients who experienced rare but severe blood clotting problems after receiving the vaccine, the CDC is investigating two other possible cases: a deceased Oregon woman and a Texas woman who was hospitalized. Of the original six women, one died and one became seriously ill. Approximately 8 million J&J vaccine doses have been administered.

Concern over the problem led the Centers for Disease Control and Prevention and the FDA to temporarily stop using the J&J vaccine in the US last week. When asked by CNBC’s Brian Sullivan whether he believes Americans will get the J&J vaccine at some point, Chen said, “Yes.”

The Advisory Committee on Immunization Practices, known as ACIP, is an external panel of experts that makes recommendations to the CDC. A meeting on the J&J vaccine was called last week, but a decision was postponed until this week. Ultimately, it is up to the CDC and the Food and Drug Administration what to do next.

Chen said ACIP now has better information about the blood clotting problems on which to base its vaccination instructions. “We’ll be able to get a good sample size. It may not be perfect, but we don’t have to be perfect to have actionable information,” said Chen, adding that he expects the panel to “get a number.” working out of recommendations that I think everyone will be happy with. “

In a statement emailed to CNBC, CDC Director Dr. Rochelle Walensky, she hopes the Public Health Agency will receive a “recommendation” that considers the risk versus benefit of using the Johnson & Johnson vaccine based on the new case data and the risk-benefit ratio analysis CDC has in last week. “

“I really appreciate the complex issue before the committee and look forward to hearing from you. I also appreciate the importance of working with the FDA to act quickly as soon as we hear about ACIP,” added Walensky .

Given the urgency of the coronavirus pandemic, some people have criticized the decision to discontinue the J&J Covid vaccine – which only requires one dose for full immunity protection – while the clot investigation was in progress.

Chen disagreed.

“The risk is very, very small, but until we could fully take into account this information we haven’t been able to contextualize this for the rest of the medical community and the public too,” he said. “We only took a 10-day break. Hopefully this won’t be detrimental in the long term, but we obviously want to instill confidence in the security information collection system.”

The other two emergency-approved Covid vaccines in the US come from Pfizer and Moderna. Both require two shots.

You might also like

Comments are closed.